Our results are aligned with these findings: in the group of patients systematically optimized, optimal AVD remained unchanged in only 11%, 51% of the patients presenting shortened AVD and 38% lengthened AVD.
The L-SNEDDS were systematically optimized using optimal mixture design, evaluated for emulsification time, globule size and in vitro drug release.
The multivariate analysis showed that standard methods were associated with improved patient rates from 60% (non-systematically optimized, n = 90) to 78% (systematically optimized, n = 9) and SonR™-based optimization was associated with improved patients' rates from 63% (non-systematically optimized, n = 27) to 86% (systematically optimized, n = 49).
The concentration of the chiral selector and organic modifier, pH of background electrolyte (BGE), capillary temperature, and applied voltage were systematically optimized by using orthogonal design and concentration of chiral selector was further optimized.
Because of savings in the systematically optimized group attributable to avoided HF hospitalizations over one year, the assumed premium for systematic optimization can be partially offset in subsequent years.
The L-SNEDDS were systematically optimized using simplex lattice design.
Extraction factors were systematically optimized by response surface methodology.
The growth conditions were systematically optimized and the as-grown doped graphene were well characterized.
Our analysis explores the cost-effectiveness of systematically optimized (SO, 3 times a year) vs. non-systematically optimized (NSO, less than 3 times a year) CRT, whatever the echo optimization method used (manual or SonR® automatic).
The present study systematically optimized EDTA extraction and was representative for production at large-scale.
This PNA-FISH method was then systematically optimized, employing response surface methodology (RS M.
